TY  - JOUR
AU  - Macut, Đuro
AU  - Opalić, Milica
AU  - Popović, Bojana
AU  - Ognjanović, Sanja
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Petrović, Tijana
AU  - Hrnčić, Dragan
AU  - Stanojlović, Olivera
AU  - Vojnović Milutinović, Danijela
AU  - Micić, Dragan
AU  - Mastorakos, George
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6329
AB  - Endocrine disruptors (EDs) are considered to have an impact on the function of reproductive axis at  different levels as well on reproductive organs in both sexes. Complexity of female reproductive system influenced with various stressors including EDs lead to morphological and functional alterations. This is resulting in modulation of neuroendocrine regulation with consequent developmental irregularities and derangements, causative infertility, endometriosis as well as premature ovarian insufficiency or polycystic ovary syndrome. A number of experimental clues was obtained on female animal models using various EDs such as synthetic estrogens and phytoestrogens, neurotransmitters, pesticides or various chemicals. These substances lead towards consequent derangement of the neuroendocrine control of reproduction from early phases of reproductive development towards different phases of adult reproductive period. This text will address some novel insights into the effects of EDs on neuroendocrine regulation of gonadal axis, effects on ovaries as well on endometrium during implantation period.
PB  - Bucharest: Acta Endocrinologica Foundation
T2  - Acta Endocrinologica (Bucharest)
T1  - The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update
IS  - 1
VL  - 19
DO  - 10.4183/aeb.2023.81
SP  - 81
EP  - 86
ER  - 

@article{
author = "Macut, Đuro and Opalić, Milica and Popović, Bojana and Ognjanović, Sanja and Bjekić-Macut, Jelica and Livadas, Sarantis and Petrović, Tijana and Hrnčić, Dragan and Stanojlović, Olivera and Vojnović Milutinović, Danijela and Micić, Dragan and Mastorakos, George",
year = "2023",
abstract = "Endocrine disruptors (EDs) are considered to have an impact on the function of reproductive axis at  different levels as well on reproductive organs in both sexes. Complexity of female reproductive system influenced with various stressors including EDs lead to morphological and functional alterations. This is resulting in modulation of neuroendocrine regulation with consequent developmental irregularities and derangements, causative infertility, endometriosis as well as premature ovarian insufficiency or polycystic ovary syndrome. A number of experimental clues was obtained on female animal models using various EDs such as synthetic estrogens and phytoestrogens, neurotransmitters, pesticides or various chemicals. These substances lead towards consequent derangement of the neuroendocrine control of reproduction from early phases of reproductive development towards different phases of adult reproductive period. This text will address some novel insights into the effects of EDs on neuroendocrine regulation of gonadal axis, effects on ovaries as well on endometrium during implantation period.",
publisher = "Bucharest: Acta Endocrinologica Foundation",
journal = "Acta Endocrinologica (Bucharest)",
title = "The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update",
number = "1",
volume = "19",
doi = "10.4183/aeb.2023.81",
pages = "81-86"
}

Macut, Đ., Opalić, M., Popović, B., Ognjanović, S., Bjekić-Macut, J., Livadas, S., Petrović, T., Hrnčić, D., Stanojlović, O., Vojnović Milutinović, D., Micić, D.,& Mastorakos, G.. (2023). The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update. in Acta Endocrinologica (Bucharest)
Bucharest: Acta Endocrinologica Foundation., 19(1), 81-86.
https://doi.org/10.4183/aeb.2023.81

Macut Đ, Opalić M, Popović B, Ognjanović S, Bjekić-Macut J, Livadas S, Petrović T, Hrnčić D, Stanojlović O, Vojnović Milutinović D, Micić D, Mastorakos G. The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update. in Acta Endocrinologica (Bucharest). 2023;19(1):81-86.
doi:10.4183/aeb.2023.81 .

Macut, Đuro, Opalić, Milica, Popović, Bojana, Ognjanović, Sanja, Bjekić-Macut, Jelica, Livadas, Sarantis, Petrović, Tijana, Hrnčić, Dragan, Stanojlović, Olivera, Vojnović Milutinović, Danijela, Micić, Dragan, Mastorakos, George, "The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update" in Acta Endocrinologica (Bucharest), 19, no. 1 (2023):81-86,
https://doi.org/10.4183/aeb.2023.81 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Vukašin, Tamara
AU  - Velija-Ašimi, Zelija
AU  - Bureković, Azra
AU  - Zdravković, Marija
AU  - Andrić, Zoran
AU  - Branković, Marija
AU  - Crevar-Marinović, Slobodanka
AU  - Mandić, Tatjana
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Livadas, Sarantis
AU  - Mastorakos, George
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4307
AB  - Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Polycystic Ovary Syndrome: A Contemporary Clinical Approach
VL  - 27
DO  - 10.2174/1381612827666210119104721
SP  - 1
EP  - 9
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Vukašin, Tamara and Velija-Ašimi, Zelija and Bureković, Azra and Zdravković, Marija and Andrić, Zoran and Branković, Marija and Crevar-Marinović, Slobodanka and Mandić, Tatjana and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Livadas, Sarantis and Mastorakos, George",
year = "2021",
abstract = "Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Polycystic Ovary Syndrome: A Contemporary Clinical Approach",
volume = "27",
doi = "10.2174/1381612827666210119104721",
pages = "1-9"
}

Bjekić-Macut, J., Vukašin, T., Velija-Ašimi, Z., Bureković, A., Zdravković, M., Andrić, Z., Branković, M., Crevar-Marinović, S., Mandić, T., Stanojlović, O., Vojnović-Milutinović, D., Livadas, S.,& Mastorakos, G.. (2021). Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design
Bentham Science Publishers., 27, 1-9.
https://doi.org/10.2174/1381612827666210119104721

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, Branković M, Crevar-Marinović S, Mandić T, Stanojlović O, Vojnović-Milutinović D, Livadas S, Mastorakos G. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design. 2021;27:1-9.
doi:10.2174/1381612827666210119104721 .

Bjekić-Macut, Jelica, Vukašin, Tamara, Velija-Ašimi, Zelija, Bureković, Azra, Zdravković, Marija, Andrić, Zoran, Branković, Marija, Crevar-Marinović, Slobodanka, Mandić, Tatjana, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Livadas, Sarantis, Mastorakos, George, "Polycystic Ovary Syndrome: A Contemporary Clinical Approach" in Current Pharmaceutical Design, 27 (2021):1-9,
https://doi.org/10.2174/1381612827666210119104721 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Mladenović, Violeta
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Andrić, Zoran
PY  - 2020
UR  - http://www.eurekaselect.com/172346/article
UR  - http://www.ncbi.nlm.nih.gov/pubmed/31146668
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3969
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.
PB  - Bentham Science Publishers Ltd.
T2  - Current Hypertension Reviews
T1  - Hypertension in Polycystic Ovary Syndrome: Novel Insights.
IS  - 1
VL  - 16
DO  - 10.2174/1573402115666190531071422
SP  - 55
EP  - 60
ER  - 

@article{
author = "Macut, Đuro and Mladenović, Violeta and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Andrić, Zoran",
year = "2020",
abstract = "Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.",
publisher = "Bentham Science Publishers Ltd.",
journal = "Current Hypertension Reviews",
title = "Hypertension in Polycystic Ovary Syndrome: Novel Insights.",
number = "1",
volume = "16",
doi = "10.2174/1573402115666190531071422",
pages = "55-60"
}

Macut, Đ., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D.,& Andrić, Z.. (2020). Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews
Bentham Science Publishers Ltd.., 16(1), 55-60.
https://doi.org/10.2174/1573402115666190531071422

Macut Đ, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews. 2020;16(1):55-60.
doi:10.2174/1573402115666190531071422 .

Macut, Đuro, Mladenović, Violeta, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Andrić, Zoran, "Hypertension in Polycystic Ovary Syndrome: Novel Insights." in Current Hypertension Reviews, 16, no. 1 (2020):55-60,
https://doi.org/10.2174/1573402115666190531071422 . .

TY  - JOUR
AU  - Macut, Djuro
AU  - Božić Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Panidis, Dimitrios
AU  - Tziomalos, Konstantinos
AU  - Vojnović Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Kastratović-Kotlica, Biljana
AU  - Petakov, Milan
AU  - Milić, Nataša
PY  - 2016
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6332
AB  - OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.
PB  - Springer Nature
T2  - Hormones
T1  - Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome
VL  - 15
DO  - 10.1007/BF03401401
SP  - 35
EP  - 44
ER  - 

@article{
author = "Macut, Djuro and Božić Antić, Ivana and Bjekić-Macut, Jelica and Panidis, Dimitrios and Tziomalos, Konstantinos and Vojnović Milutinović, Danijela and Stanojlović, Olivera and Kastratović-Kotlica, Biljana and Petakov, Milan and Milić, Nataša",
year = "2016",
abstract = "OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.",
publisher = "Springer Nature",
journal = "Hormones",
title = "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome",
volume = "15",
doi = "10.1007/BF03401401",
pages = "35-44"
}

Macut, D., Božić Antić, I., Bjekić-Macut, J., Panidis, D., Tziomalos, K., Vojnović Milutinović, D., Stanojlović, O., Kastratović-Kotlica, B., Petakov, M.,& Milić, N.. (2016). Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones
Springer Nature., 15, 35-44.
https://doi.org/10.1007/BF03401401

Macut D, Božić Antić I, Bjekić-Macut J, Panidis D, Tziomalos K, Vojnović Milutinović D, Stanojlović O, Kastratović-Kotlica B, Petakov M, Milić N. Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. in Hormones. 2016;15:35-44.
doi:10.1007/BF03401401 .

Macut, Djuro, Božić Antić, Ivana, Bjekić-Macut, Jelica, Panidis, Dimitrios, Tziomalos, Konstantinos, Vojnović Milutinović, Danijela, Stanojlović, Olivera, Kastratović-Kotlica, Biljana, Petakov, Milan, Milić, Nataša, "Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome" in Hormones, 15 (2016):35-44,
https://doi.org/10.1007/BF03401401 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bačević, Marina
AU  - Božić-Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Civcic, Milorad
AU  - Erceg, Snježana
AU  - Vojnović-Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Andrić, Zoran
AU  - Kastratović-Kotlica, Biljana
AU  - Sukilović, Tijana
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2071
AB  - Background. Women with polycystic ovary syndrome (PCOS) could develop
   subclinical atherosclerosis during life. Purpose. To analyze
   cardiovascular risk (CVR) factors and their relation to clinical markers
   of cardiovascular disease (CVD) in respect to their age. Material and
   Methods. One hundred women with PCOS (26.32 +/- 5.26 years, BMI: 24.98
   +/- 6.38 kg/m(2)) were compared to 50 respective controls. In all
   subjects, total cholesterol (TC), HDL-C, LDL-C, triglycerides, TC/HDL-C
   and TG/HDL-C ratios, glucose, insulin and HOMA index, waist-to-hip ratio
   (WHR), systolic and diastolic blood pressure (SBP and DBP, resp.), and
   carotid intima-media thickness (CIMT) were analyzed in respect to their
   age and level of androgens. Results. PCOS over 30 years had higher WHR
   (P = 0.008), SBP (P < 0.001), DBP (P < 0.001), TC (P = 0.028), HDL-C (P
   = 0.028), LDL-C (P = 0.045), triglycerides (P < 0.001), TC/HDL-C (P <
   0.001), and triglycerides/HDL-C (P < 0.001) and had more prevalent
   hypertension and pronounced CIMT on common carotid arteries even after
   adjustment for BMI (P = 0.005 and 0.036, resp.). TC/ HDL-C and TG/HDL-C
   were higher in PCOS with the highest quintile of FAI in comparison to
   those with lower FAI (P = 0.045 and 0.034, resp.). Conclusions. PCOS
   women older than 30 years irrespective of BMI have the potential for
   early atherosclerosismirrored through the elevated lipids/lipid ratios
   and through changes in blood pressure.
T2  - International Journal of Endocrinology
T1  - Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure
IS  - 812610
DO  - 10.1155/2015/812610
ER  - 

@article{
author = "Macut, Đuro and Bačević, Marina and Božić-Antić, Ivana and Bjekić-Macut, Jelica and Civcic, Milorad and Erceg, Snježana and Vojnović-Milutinović, Danijela and Stanojlović, Olivera and Andrić, Zoran and Kastratović-Kotlica, Biljana and Sukilović, Tijana",
year = "2015",
abstract = "Background. Women with polycystic ovary syndrome (PCOS) could develop
   subclinical atherosclerosis during life. Purpose. To analyze
   cardiovascular risk (CVR) factors and their relation to clinical markers
   of cardiovascular disease (CVD) in respect to their age. Material and
   Methods. One hundred women with PCOS (26.32 +/- 5.26 years, BMI: 24.98
   +/- 6.38 kg/m(2)) were compared to 50 respective controls. In all
   subjects, total cholesterol (TC), HDL-C, LDL-C, triglycerides, TC/HDL-C
   and TG/HDL-C ratios, glucose, insulin and HOMA index, waist-to-hip ratio
   (WHR), systolic and diastolic blood pressure (SBP and DBP, resp.), and
   carotid intima-media thickness (CIMT) were analyzed in respect to their
   age and level of androgens. Results. PCOS over 30 years had higher WHR
   (P = 0.008), SBP (P < 0.001), DBP (P < 0.001), TC (P = 0.028), HDL-C (P
   = 0.028), LDL-C (P = 0.045), triglycerides (P < 0.001), TC/HDL-C (P <
   0.001), and triglycerides/HDL-C (P < 0.001) and had more prevalent
   hypertension and pronounced CIMT on common carotid arteries even after
   adjustment for BMI (P = 0.005 and 0.036, resp.). TC/ HDL-C and TG/HDL-C
   were higher in PCOS with the highest quintile of FAI in comparison to
   those with lower FAI (P = 0.045 and 0.034, resp.). Conclusions. PCOS
   women older than 30 years irrespective of BMI have the potential for
   early atherosclerosismirrored through the elevated lipids/lipid ratios
   and through changes in blood pressure.",
journal = "International Journal of Endocrinology",
title = "Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure",
number = "812610",
doi = "10.1155/2015/812610"
}

Macut, Đ., Bačević, M., Božić-Antić, I., Bjekić-Macut, J., Civcic, M., Erceg, S., Vojnović-Milutinović, D., Stanojlović, O., Andrić, Z., Kastratović-Kotlica, B.,& Sukilović, T.. (2015). Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure. in International Journal of Endocrinology(812610).
https://doi.org/10.1155/2015/812610

Macut Đ, Bačević M, Božić-Antić I, Bjekić-Macut J, Civcic M, Erceg S, Vojnović-Milutinović D, Stanojlović O, Andrić Z, Kastratović-Kotlica B, Sukilović T. Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure. in International Journal of Endocrinology. 2015;(812610).
doi:10.1155/2015/812610 .

Macut, Đuro, Bačević, Marina, Božić-Antić, Ivana, Bjekić-Macut, Jelica, Civcic, Milorad, Erceg, Snježana, Vojnović-Milutinović, Danijela, Stanojlović, Olivera, Andrić, Zoran, Kastratović-Kotlica, Biljana, Sukilović, Tijana, "Predictors of Subclinical Cardiovascular Disease in Women with
 Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and
 Arterial Blood Pressure" in International Journal of Endocrinology, no. 812610 (2015),
https://doi.org/10.1155/2015/812610 . .